Table 1 Univariate analysis of factors associated with bleeding events during CA with uninterrupted periprocedural edoxaban
Factors | Univariate OR (95% CI) | p-value |
|---|---|---|
Sex | ||
Female vs male | 1.182 (0.397–3.519) | 0.7633 |
Age, years | ||
65–74 vs < 65 | 2.604 (0.682–9.949) | 0.1617 |
≥ 75 vs < 65 | 3.835 (0.839–17.542) | 0.0831 |
AF type | ||
Non-paroxysmal vs paroxysmal | 2.144 (0.752–6.116) | 0.1539 |
CA surgical type | ||
Radiofrequency vs cryoballoon | 1.948 (0.433–8.765) | 0.3848 |
CHADS2 score | ||
≥ 2 vs < 2 | 2.194 (0.781–6.162) | 0.1360 |
HAS-BLED score | ||
≥ 3 vs < 3 | 9.478 (2.363–38.014) | 0.0015 |
Renal function (CrCL), mL/min | ||
≤ 50 vs > 50 | 10.594 (3.645–30.790) | < 0.0001 |
Edoxaban dose the day before CA, mg | ||
30 vs 60 | 3.492 (1.175–10.378) | 0.0245 |
Time from CA termination to restart of edoxaban administration on the day of CA, hours | ||
≥ 3 and < 6 vs < 3 | 1.159 (0.127–10.570) | 0.8956 |
≥ 6 vs < 3 | 2.124 (0.261–17.314) | 0.4817 |
Plasma concentration of edoxaban before CA (ng/mL) | 1.005 (0.974–1.038) | 0.7331 |
Perioperative heparin dose (unit) | 1.003 (0.993–1.013) | 0.5387 |
Maximum ACT during CA (s) | 1.011 (0.951–1.075) | 0.7222 |